Memory, Menopause, and Blood Sugar

Evidence Review

Scholey et al. (2008) — Sage extract and memory in healthy older adults [1]

This double-blind, placebo-controlled crossover trial enrolled 20 volunteers over age 65 (mean age 72.95). Participants received four different doses of sage extract (167, 333, 666, and 1332 mg) and placebo in a randomized order, with 7-day washout periods between visits. The primary outcome measure was the Cognitive Drug Research computerized assessment battery, covering attention, working memory, and secondary memory. The 333 mg dose produced the most robust results: significant enhancement of secondary memory performance at all testing time points (1, 2.5, 4, and 6 hours post-dose) compared to placebo. The 167 mg dose showed weaker effects, while the higher doses (666 and 1332 mg) paradoxically showed diminished effects compared to the middle dose, consistent with an inverted-U dose-response curve common in cognition research. The mechanism was attributed to cholinesterase inhibition confirmed in in vitro assays of the same extract. This study was important for establishing that sage's cognitive effects in animal models translated to humans.

Wightman et al. (2021) — Acute and chronic cognitive effects in adults [2]

This randomized, double-blind, placebo-controlled, parallel groups study enrolled 94 healthy participants (25 male, 69 female, ages 30–60) over 29 days, with neuropsychological assessments at baseline, day 1 (acute), and day 29 (chronic). The sage treatment group (n=45) and placebo group (n=49) completed the study. The sage combination extract produced consistent, statistically significant improvements on working memory and accuracy measures: Corsi Blocks (spatial working memory), Numeric Working Memory, and Name to Face Recall tasks. Notably, the effects were present acutely (day 1) and grew stronger after 29 days of daily use, suggesting that the cognitive benefits accumulate over time rather than being a single-dose effect. The authors proposed that chronic cholinesterase inhibition combined with the antioxidant and anti-inflammatory effects of rosmarinic acid and other polyphenols produces progressive neuroprotective benefits. Effect sizes were moderate (Cohen's d approximately 0.4–0.6 on key measures), which is meaningful for a dietary supplement in a healthy population.

Bommer, Klein, and Suter (2011) — Sage for menopausal hot flushes [3]

This multicenter open clinical trial conducted across eight Swiss general practices enrolled 71 postmenopausal women (mean age 56.4 years, menopausal for at least 12 months, experiencing at least 5 hot flashes daily). All participants received one tablet of fresh sage leaves daily for 8 weeks following a 1-week baseline observation period. The primary endpoint was change in hot flash frequency and severity. Results were striking: by week 4, total hot flash intensity had decreased by 50%; by week 8 the decrease reached 64%. Breaking down by severity — mild hot flashes decreased by 46%, moderate by 62%, severe by 79%, and very severe hot flashes by 100% over the full 8 weeks. Night sweats and other menopausal complaints also improved. The tolerability profile was excellent, with no serious adverse events. The limitation of this study is the open-label design without a placebo control, meaning a placebo effect cannot be fully excluded. However, the magnitude and dose-gradient of the response across severity categories suggests a genuine pharmacological effect beyond expectation for placebo.

Moradi et al. (2023) — Meta-analysis of sage for hot flashes [4]

This systematic review and meta-analysis searched PubMed, Web of Science, Cochrane, Scopus, SID, and Magiran, identifying 4 eligible randomized controlled trials including 310 postmenopausal women. Meta-analysis found that Salvia officinalis significantly reduced the frequency of hot flashes compared to placebo (pooled effect statistically significant). The effect on severity did not reach significance across pooled trials, possibly due to heterogeneity in severity measurement methods. The authors recommended Salvia officinalis as a candidate for inclusion in menopausal management guidelines, noting its favorable safety profile. Limitations include the small number of eligible trials and heterogeneity in preparation, dose, and duration.

Kianbakht and Dabaghian (2013) — Glycemic control RCT [5]

This double-blind randomized placebo-controlled trial enrolled 80 hyperlipidemic type 2 diabetic patients who were randomized to sage leaf extract (500 mg capsule three times daily = 1,500 mg/day) or matched placebo for 3 months. At endpoint, the sage group showed significant reductions compared to placebo in: fasting blood glucose (-18 mg/dL vs. placebo), HbA1c (-0.9% vs. placebo), total cholesterol (-23 mg/dL), triglycerides (-28 mg/dL), and LDL-C (-21 mg/dL), while HDL-C increased (+4 mg/dL). No significant adverse effects were reported. The magnitude of HbA1c reduction (approximately 0.9%) is clinically relevant and comparable to the effects of some pharmaceutical antidiabetic adjuncts. The study population was patients not at glycemic targets despite existing treatment, meaning sage was studied as an add-on rather than as monotherapy.

Jafarizadeh et al. (2022) — Meta-analysis of glycemic effects [6]

This systematic review and meta-analysis in the Journal of Diabetes and Metabolic Disorders pooled data from multiple randomized clinical trials. Meta-analysis results showed statistically significant reductions in fasting blood sugar (MD: −31.15 mg/dL; 95% CI: −37.56 to −24.73; p<0.00001) and HbA1c (MD: −0.94%; 95% CI: −1.25 to −0.63; p<0.00001) in patients receiving Salvia officinalis versus placebo. Total cholesterol also improved significantly. The authors noted that the number of eligible trials was small and called for larger, longer-duration trials before clinical guidelines could be updated. The effect size for HbA1c reduction, while promising, falls in the range that would be considered moderate by conventional clinical standards.

Strength of evidence summary: Sage has unusually strong human clinical evidence for a culinary herb. Memory and cognition are supported by at least two double-blind randomized trials with consistent findings. Menopausal hot flash reduction is supported by one open trial and one meta-analysis of four RCTs — the evidence base is solid for frequency reduction though less conclusive for severity. Blood sugar effects are supported by one high-quality RCT and a confirmatory meta-analysis. The pharmacological mechanisms are well understood, lending biological plausibility to all three areas. The main research gaps are long-term safety data for sustained high-dose use and larger trials in each therapeutic area.